- Home
- IMMX vs UNCY Comparison
IMMX vs UNCY Comparison
Compare IMMX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- UNCY
- Stock Information
- Founded
- IMMX 2014
- UNCY 2016
- Country
- IMMX United States
- UNCY United States
- Employees
- IMMX N/A
- UNCY N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- UNCY Health Care
- Exchange
- IMMX Nasdaq
- UNCY Nasdaq
- Market Cap
- IMMX 50.1M
- UNCY 58.7M
- IPO Year
- IMMX 2021
- UNCY 2021
- Fundamental
- Price
- IMMX $1.75
- UNCY $0.57
- Analyst Decision
- IMMX Strong Buy
- UNCY Strong Buy
- Analyst Count
- IMMX 1
- UNCY 3
- Target Price
- IMMX $7.00
- UNCY $5.33
- AVG Volume (30 Days)
- IMMX 47.5K
- UNCY 787.6K
- Earning Date
- IMMX 05-08-2025
- UNCY 05-12-2025
- Dividend Yield
- IMMX N/A
- UNCY N/A
- EPS Growth
- IMMX N/A
- UNCY N/A
- EPS
- IMMX N/A
- UNCY N/A
- Revenue
- IMMX N/A
- UNCY N/A
- Revenue This Year
- IMMX N/A
- UNCY N/A
- Revenue Next Year
- IMMX N/A
- UNCY N/A
- P/E Ratio
- IMMX N/A
- UNCY N/A
- Revenue Growth
- IMMX N/A
- UNCY N/A
- 52 Week Low
- IMMX $1.26
- UNCY $0.20
- 52 Week High
- IMMX $3.13
- UNCY $1.60
- Technical
- Relative Strength Index (RSI)
- IMMX 41.38
- UNCY 44.85
- Support Level
- IMMX $1.64
- UNCY $0.60
- Resistance Level
- IMMX $1.90
- UNCY $0.65
- Average True Range (ATR)
- IMMX 0.14
- UNCY 0.05
- MACD
- IMMX 0.00
- UNCY -0.00
- Stochastic Oscillator
- IMMX 10.44
- UNCY 11.20
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.